Trial Profile
A Phase II Trial of leukocyte stem cell therapy (ApoCell; Enlivex Therapeutics) for steroid-refractory Graft-versus-host disease
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 15 Sep 2020
Price :
$35
*
At a glance
- Drugs Leukocyte-cell-therapy-Enlivex-Therapeutics (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Sponsors Enlivex Therapeutics
- 19 Nov 2018 According to an Enlivex Therapeutics media release, study is expected to strat in Q4 2019.
- 28 Jan 2015 New trial record